Cargando…
17-Alpha-Hydroxyprogesterone vs. Placebo for Preventing of Recurrent Preterm Birth: A Systematic Review and Meta-Analysis of Randomized Trials
Background: Preterm birth (PTB) is a leading cause of neonatal morbidity and mortality. Objective: To estimate the effect of 17-alpha-hydroxyprogesterone caproate (17-OHPC) compared to placebo in singleton gestations for reducing the risk of recurrent PTB and neonatal morbidity and mortality. Work D...
Autores principales: | Almutairi, Abdulaali R., Aljohani, Hadir I., Al-fadel, Nouf S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671739/ https://www.ncbi.nlm.nih.gov/pubmed/34926508 http://dx.doi.org/10.3389/fmed.2021.764855 |
Ejemplares similares
-
Patient and Provider Perspectives on Acceptability, Access, and Adherence to 17-Alpha-Hydroxyprogesterone Caproate for Preterm Birth Prevention
por: Garcia, Stephanie M., et al.
Publicado: (2021) -
Comparison of oral Dydrogesterone and 17-α hydroxyprogesterone caprate in the prevention of preterm birth
por: Alizadeh, Fahimeh, et al.
Publicado: (2022) -
Weekly 17 alpha-hydroxyprogesterone caproate to prevent preterm birth among women living with HIV: a randomised, double-blind, placebo-controlled trial
por: Price, Joan T, et al.
Publicado: (2021) -
Evaluation the effect of 17-alpha hydroxyprogesterone caproate on gestational diabetes mellitus in pregnant women at risk for preterm birth
por: Rouholamin, Safoura, et al.
Publicado: (2015) -
17-Hydroxyprogesterone Caproate for the Prevention of Recurrent Preterm Birth – A Systematic Review and Meta-analysis Taking into Account the PROLONG Trial
por: Kuon, Ruben-J., et al.
Publicado: (2021)